Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the issuance of non-qualified stock option awards as part of its compensation strategy. On May 12, 2025, the company granted options to purchase a total of 160,000 shares of common stock to two newly hired employees. These options, issued outside of the 2021 Long-Term Performance Incentive Plan, are aligned with Nasdaq Listing Rule 5635(c)(4). The exercise prices are set at $0.839 and $0.78 per share, corresponding to the closing prices on the respective grant dates of May 5 and May 12, 2025. The stock options come with a 10-year term and a four-year vesting schedule, beginning with one-fourth of the shares vesting after the first year, followed by monthly installments, contingent on the employees' continued service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.